1.	A Phase I/II Study of the Photon Radiosurgery System Phase: Phase II, Phase I Type: Treatment Status: Active Age: 2 to 32 Sponsor: Pharmaceutical / Industry Protocol IDs: CNS 0201, NCT00179907
2.	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
3.	Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 21 Sponsor: Other Protocol IDs: 10-096, NCT01294670
4.	Antineoplaston Therapy in Treating Children With Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
5.	Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
6.	Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation Phase: Phase II Type: Natural history/Epidemiology, Treatment Status: Active Age: 1 to 25 Sponsor: NCI, Other Protocol IDs: 10-206, NCT01288235
7.	A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection Phase: Phase II Type: Treatment Status: Active Age: 0 to 21 Sponsor: Other Protocol IDs: RT2CR, NCT01419067
8.	Phase I Study of Photodynamic Therapy With Benzoporphyrin Derivative Monoacid Ring A in Patients With Refractory Brain Tumors. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase I Type: Treatment Status: Active Age: 3 to 70 Sponsor: Other Protocol IDs: MCW-7594, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647
9.	A Trial of RAD001 and Avastin in Children With Recurrent Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: RADBEV, NCT00756340
10.	Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 months to 23 years Sponsor: Other Protocol IDs: ACH-CNS-001, NCT00876993
11.	Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 21 Sponsor: Other Protocol IDs: SorIrin1576, NCT01518413
12.	Photodynamic Therapy (PDT) for Brain Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: 163588-1, NCT01682746
13.	Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 18 Sponsor: Pharmaceutical / Industry Protocol IDs: TED12689, U1111-1128-5704, NCT01751308
14.	Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 2 to 25 Sponsor: Other Protocol IDs: 2005P001629, NCT01115777
15.	Auto Transplant for High Risk or Relapsed Solid Tumor Phase: No phase specified Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 2011OC057, MT2011-09C, NCT01505569